No connection

Search Results

BFRI vs SINT

BFRI
Biofrontera Inc.
BEARISH
Price
$0.86
Market Cap
$10.0M
Sector
Healthcare
AI Confidence
92%
SINT
Sintx Technologies, Inc.
BEARISH
Price
$2.69
Market Cap
$11.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BFRI
--
SINT
--
Forward P/E
BFRI
-3.72
SINT
-1.53
P/B Ratio
BFRI
-3.85
SINT
3.64
P/S Ratio
BFRI
0.27
SINT
10.89
EV/EBITDA
BFRI
-0.65
SINT
-1.0

Profitability

Gross Margin
BFRI
64.41%
SINT
45.28%
Operating Margin
BFRI
-89.84%
SINT
-787.59%
Profit Margin
BFRI
-47.28%
SINT
0.0%
ROE
BFRI
-1191.73%
SINT
-303.8%
ROA
BFRI
-64.91%
SINT
-69.8%

Growth

Revenue Growth
BFRI
-22.5%
SINT
-46.5%
Earnings Growth
BFRI
--
SINT
--

Financial Health

Debt/Equity
BFRI
--
SINT
1.11
Current Ratio
BFRI
1.15
SINT
1.51
Quick Ratio
BFRI
0.51
SINT
1.16

Dividends

Dividend Yield
BFRI
--
SINT
--
Payout Ratio
BFRI
0.0%
SINT
0.0%

AI Verdict

BFRI BEARISH

BFRI exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of Altman Z-Score data, which raises red flags for potential bankruptcy risk. The company reports massive losses with a -47.28% profit margin, negative ROE (-1191.73%), and declining revenue (YoY -22.50%). Despite a strong gross margin (64.41%), operational inefficiencies and negative cash flows undermine sustainability. The stock trades at a deep discount (Price/Sales: 0.27), but this is not a value signal—rather, it reflects deteriorating fundamentals and investor skepticism. Analysts' 'strong_buy' recommendation appears disconnected from the underlying data.

Strengths
High gross margin (64.41%) suggests potential pricing power or low production costs
Recent 1-month price increase (+3.1%) indicates short-term momentum
Analyst consensus is 'strong_buy' despite poor fundamentals, suggesting potential catalyst expectations
Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational performance
Negative ROE (-1191.73%) and ROA (-64.91%) signal severe capital inefficiency and loss of shareholder value
Consistent earnings misses in the last 4 quarters (0/4 beats, average surprise -88.35%) reflect deteriorating execution
SINT BEARISH

SINT exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -787.59%. The company is experiencing a collapse in its top line with YoY revenue growth at -46.50% and a consistent track record of missing earnings estimates (0/4 beats in the last year). Despite a 'Strong Buy' analyst consensus and a target price of $10.17, the fundamental data suggests a company in a death spiral with a 5-year price change of -100%. The disconnect between analyst optimism and the deterministic health scores indicates extreme speculative risk.

Strengths
Positive Gross Margin (45.28%) suggesting some product-level viability
Current Ratio of 1.51 provides a minimal short-term liquidity buffer
Quick Ratio of 1.16 indicates ability to cover immediate liabilities
Risks
Severe revenue contraction (-46.50% YoY)
Extreme operational inefficiency (Operating Margin -787.59%)
Massive equity erosion (ROE -303.80%)

Compare Another Pair

BFRI vs SINT: Head-to-Head Comparison

This page compares Biofrontera Inc. (BFRI) and Sintx Technologies, Inc. (SINT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile